ZF2001

ZF2001
Logo
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Trade namesZifivax
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.[2][3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.[4][5]

ZF2001 employs technology similar to other protein-based vaccines[6] in Phase III trials from Novavax, Vector Institute, and Medicago.[7]

ZF2001 was first approved for use in Uzbekistan and later China.[8][9] Production capacity is expected to be one billion doses a year in China[10] and 200 million in Uzbekistan.[11] By July, 100 million doses had been administered in China and Uzbekistan.[12]

  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ "Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 December 2020.
  3. ^ "COVID-19 Vaccine: ZIFIVAX by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences". covidvax.org. Archived from the original on 30 January 2021. Retrieved 27 December 2020.
  4. ^ "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. 20 November 2020. Retrieved 27 December 2020.
  5. ^ Ying TP (7 December 2020). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". NST Online. Retrieved 27 December 2020.
  6. ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
  7. ^ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 27 December 2020.
  8. ^ Cite error: The named reference :6 was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference :5 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference :7 was invoked but never defined (see the help page).
  11. ^ "ZF-UZ-VAC-2001 vaccine to be produced in Uzbekistan". UzDaily.uz (in Russian). Retrieved 28 July 2021.
  12. ^ Liu R (17 July 2021). "China Zhifei's COVID shot largely retains effect against Delta variant-lab study". Reuters. Retrieved 17 July 2021.